MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Home・Aandelen Lijst・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

1.86 2.2

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.8599999999999999

Max

1.8900000000000001

Belangrijke statistieken
By Trading Economics
Inkomsten	-2.8M -16M
Verkoop	-8.7M 5.5M
Winstmarge	-282.723
Werknemers	81
EBITDA	-4.2M -15M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+104.81% upside

Dividenden
By Dow Jones
Volgende Winsten	12 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	73M 724M
Vorige openingsprijs	-0.34
Vorige sluitingsprijs	1.86

Nieuwssentiment

By Acuity

95%

1 / 348 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

0.6863 / 0.72 Steun & Weerstand

Lexicon Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 apr 2026, 20:26 UTC

Acquisities, Fusies, Overnames

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

17 apr 2026, 18:15 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

17 apr 2026, 16:49 UTC

Belangrijke Nieuwsgebeurtenissen

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

18 apr 2026, 01:00 UTC

Belangrijke Nieuwsgebeurtenissen

As Economic Pressures Mount, Will Iran or the U.S. Blink First? -- WSJ

17 apr 2026, 22:58 UTC

Winsten

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17 apr 2026, 21:32 UTC

Marktinformatie

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17 apr 2026, 21:22 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

17 apr 2026, 21:22 UTC

Marktinformatie

Moody's Downgrades Belgium to A1 -- Market Talk

17 apr 2026, 20:52 UTC

Winsten

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17 apr 2026, 20:50 UTC

Marktinformatie

Winsten

Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

17 apr 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

17 apr 2026, 20:29 UTC

Winsten

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

17 apr 2026, 20:11 UTC

Acquisities, Fusies, Overnames

UCB to Buy Neurona Therapeutics for Up to $1.15B

17 apr 2026, 19:34 UTC

Marktinformatie

Winsten

Acquisities, Fusies, Overnames

Global Equities Roundup: Market Talk

17 apr 2026, 19:34 UTC

Marktinformatie

Winsten

Acquisities, Fusies, Overnames

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

17 apr 2026, 19:31 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

17 apr 2026, 19:26 UTC

Marktinformatie

U.S. Natural Gas Futures Edge Up -- Market Talk

17 apr 2026, 19:21 UTC

Marktinformatie

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

17 apr 2026, 19:15 UTC

Marktinformatie

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

17 apr 2026, 19:07 UTC

Marktinformatie

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

17 apr 2026, 18:57 UTC

Belangrijke Nieuwsgebeurtenissen

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

17 apr 2026, 18:53 UTC

Acquisities, Fusies, Overnames

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

17 apr 2026, 18:53 UTC

Acquisities, Fusies, Overnames

UCB 2026 Rev Guidance Unchanged

17 apr 2026, 18:52 UTC

Acquisities, Fusies, Overnames

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

17 apr 2026, 18:52 UTC

Acquisities, Fusies, Overnames

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

17 apr 2026, 18:14 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

17 apr 2026, 18:00 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

17 apr 2026, 18:00 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

17 apr 2026, 17:31 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

17 apr 2026, 17:26 UTC

Marktinformatie

Winsten

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

Peer Vergelijking

Prijswijziging

Lexicon Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

104.81% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 3.83 USD 104.81%

Hoogste 6 USD

Laagste 1 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Lexicon Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Lexicon Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

0.6863 / 0.72Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

1 / 348 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.